Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy
MOH_2018-10-16_003702Phase 3Not yet recruiting
- Sponsor
- MyoKardia
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Mavacamten with Placebo (2 arms). Primary endpoint: Safety and efficacy of mavacamten compared with placebo. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on MOH_2018-10-16_003702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-16_003702.